|
Research Ideas and Outcomes :
Grant Proposal
|
|
Corresponding author: Affif Grazette (affif.grazette@wur.nl)
Received: 22 Apr 2026 | Published: 03 Jun 2026
© 2026 Affif Grazette, Baruch Rinkevich, Shirley Pomponi, Miroslava Atanassova, Ólafur Friðjónsson, Marco Giovine, Marina Pozzolini, Giuseppe Falvo D`Urso Labate, Dirk Martens, Antoinette Kazbar, Tiago Silva, Torsten Thomas, Rene Wijffels
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Grazette A, Rinkevich B, Pomponi S, Atanassova M, Friðjónsson Ó, Giovine M, Pozzolini M, Falvo D`Urso Labate G, Martens D, Kazbar A, Silva T, Thomas T, Wijffels R (2026) Bioprocesses for Metabolite Production from Marine Invertebrates: The European Horizon BLUES project. Research Ideas and Outcomes 12: e196757. https://doi.org/10.3897/rio.12.e196757
|
|
One of the major accomplishments of the 20th century is the advancement of pharmaceuticals to treat a variety of diseases and metabolic disorders. Traditionally, nature has served as the primary source for new pharmaceuticals, with over 50% of marketed drugs either derived directly from natural sources or synthesised using natural products as templates or starting materials. The ocean is home to more than 200,000 described species of marine invertebrates, representing every phylum, including twelve phyla that are exclusively marine. More than 15,000 novel marine-derived chemicals have been reported, many of which have potential pharmaceutical applications. Many of these compounds occur in marine organisms at very low concentrations and their often complex molecular structures make them difficult to be chemically synthesised, which has created a bottleneck in their development as drugs. Scientists have spent decades, without success, working to develop alternative supply options, including in vitro culturing of marine invertebrates or cell cultures. The objective of BLUES is to expand the potential to produce valuable and unique bioactive compounds from marine invertebrates by developing novel in vitro cell culture systems for four phyla of marine invertebrates (Porifera, Cnidaria, Echinodermata, Chordata) and optimising production yields as an alternative to wild harvesting and chemical synthesis. The goal is to design a pathway towards industrial bioprocesses using cell lines as a chassis to produce unique, high-value, marine bio-based compounds. The novel bioprocesses will solve the supply bottleneck for increased availability of bioactive compounds, but also for a higher level of sustainable alternatives, contributing to the development of circular processing and a circular economy.
The BLUES project is supported by the Horizon Europe, European Union research initiative, project number: 101134820.
Biotechnology, sustainability, cell line development, bioprocess development, marine invertebrates, bioactive secondary metabolites, circular economy, hybridoma, deep eutectic solvents, 3D cell culture, scaffold materials/matrices
The oceans cover over 70% of Earth’s surface and 95% of Earth’s biosphere and contain a wealth of biological diversity with more than 200,000 described species of marine invertebrates and algae and millions of microbial species (
Such compounds are being exploited for potential industrial uses, such as pharmaceuticals, cosmetics, nutritional supplements, molecular probes, enzymes, anti-foulants, fine chemicals and agrichemicals (
Marine organisms produce a wide range of bioactive metabolites with potential human health applications, including those that have cytotoxic, antioxidant and antimicrobial properties. Marine invertebrates share a surprisingly high level of homology with more developed metazoans (
Marine-derived bioactive compounds can also address the rising demand for alternative nutraceuticals (
Despite the vast potential for marine compounds to act as new pharmaceuticals, cosmetics, nutritional supplements, molecular probes, catalysts, anti-foulants, fine chemicals, agrichemicals and other innovative bioproducts, the major bottleneck to the development of this biotechnological sector remains the limited supply of raw materials. Harvesting wild organisms from the marine environment is not ecologically sustainable, as many of the novel marine compounds are found only in minute quantities and are often only synthesised under special conditions (
The BLUES consortium has been assembled to tackle this research challenge regarding the development of cell cultures from marine invertebrates. It is comprised of experts in cell culture of the four taxa of invertebrates (Porifera, Cnidaria, Echinodermata, Urochordata); marine invertebrate-microbe symbiosis; product down-stream processing; process intensification; and communication, exploitation and dissemination (Fig.
|
Partner |
Country |
|
Wageningen University |
Netherlands |
|
Moreforsking AS |
Norway |
|
Israel Oceanographic and Limnological Research Limited |
Israel |
|
Matis OHF |
Iceland |
|
Universidade Do Minho |
Portugal |
|
Universita Degli Studi Di Genova |
Italy |
|
Geonardo Kornyezetvedelmi Terinformatikai Es Regionalis Projektfejleszto Korlatolt Felelossegu Tarsasag |
Hungary |
|
Cellex SRL |
Italy |
|
University of New South Wales |
Australia |
In vitro production, generating bioactive compounds through cell cultures, has been considered as a promising solution for the supply problem, as it enables controlled cultivation conditions to increase both biomass quality and product yield (
A key motivation of the BLUES consortium is to develop reliable methodologies for continuously proliferating cell cultures from marine invertebrates. This development is based on an earlier EU Horizon 2020 grant agreement (No. 679849), where the first marine invertebrate (sponge) cell line that exhibited rapid cell doubling rates (more than 100 population doublings) was established (
Table
Species (AphiaID) and metabolites (PubChem CID) of interest for the BLUES project. Additional species from each of the four phyla may also be explored, depending on sample availability and time constraints.
|
Phylum |
Species |
Metabolite(s) of interest |
|
Porifera |
Geodia barretti (134023) Axinella corrugata (165472) |
Barettins (11177588)/Barretides Stevensine (11003581) |
|
Cnidaria |
Stylophora pistillata (206982) |
Mycosporine-like amino acids |
|
Echinodermata |
Parastichopus tremulus (124535) Cucumaria frondosa (124612) |
Bioactive peptides/ Fucoidan (92023653)/ Saponins (6540709) Frondoside (44448161)/ Collagen |
|
Chordata |
Botryllus schlosseri (103862) |
Botryllin |
In line with this objective, WP2 is dedicated to developing primary cell cultures and establishing continuously dividing cell lines from four phyla of marine invertebrates: Porifera (sponges), Cnidaria (corals), Echinodermata (sea cucumbers) and Chordata (ascidians) (Table
Secondary metabolites extracted from wild-harvested marine invertebrates are typically present in low concentrations. These low yields make extraction unsustainable, as the biomass required would place significant pressure on natural populations, threatening species’ viability. This creates a harmful cycle in which increasing demand leads to overharvesting, further endangering marine biodiversity. Moreover, variability in metabolite content due to environmental factors makes wild harvesting an unreliable and inconsistent source for large-scale production.
Deep eutectic solvents (DESs) have emerged as promising green solvents, gaining considerable attention in both academia and industry in recent years due to their low toxicity, non-volatility, low vapour pressure, high boiling point and ease of preparation. DES are typically formed through mixtures of Bronsted or Lewis acids and bases, usually involving at least one hydrogen bond donor (HBD) and a hydrogen bond acceptor (HBA), resulting in a eutectic system (Fig.
Recently, we developed a complete extraction process using DES for isolating lipids from the microalga Nannochloropsis oceanica (
As noted earlier, extraction yields of marine-derived metabolites are often low. The BLUES project addresses this challenge through two key strategies: increasing product yields and intensifying the overall production process. To enhance metabolite yields, several approaches will be implemented, including the optimisation of culture media tailored to species-specific needs, investigating the genetic mechanisms underlying metabolite biosynthesis, the use of hybridoma technology and exploring co-culture systems involving invertebrate hosts and their algal or microbial symbionts.
One major strategy for culturing sponge cells has involved adapting existing mammalian cell culture media by supplementing them with salts to mimic sea water (formulations such as Marine M199) and incorporating additional components, such as growth factors to stimulate cell proliferation (
We further investigated the in vitro responses of various blood cell types from Botryllus (a model colonial tunicate), using five distinct formulations of cell culture media (
Understanding the relationship between gene expression patterns, specifically, genes that are up- or down-regulated and the production of bioactive compounds is key to deciphering the complex biosynthetic pathways involved. This knowledge can provide information for strategies to enhance metabolite yields and clarify whether these compounds originate from the host invertebrate, its microbial symbionts or both (
WP2 will also explore the development of co-culture systems of coral cell with algal symbionts as well as sponge cell with microbial symbionts. The underlying rationale is that co-cultivation with symbionts may enhance the longevity and proliferation of invertebrate cell cultures. In the case of corals, maintaining a functional association with symbiotic algae could support sustained cell growth by boosting biomass and promoting continuous cell division. These algae, which reside within the coral’s endodermal cells, provide a major portion of the host’s energy requirements through the translocation of photosynthetically fixed carbon, while the coral cells actively regulate the physiology of their symbionts, creating a mutually beneficial interaction (
In the case of the sponge Geodia barretti, it is believed that barettins are produced either through the symbiotic relationship between the sponge and its associated microbes or by the microbial symbionts alone (
In situations where bioactive compounds originate from species whose cells cannot be cultured or where biosynthetic pathways are unknown or difficult to engineer, hybridoma technology offers a viable alternative for developing production strains. Traditionally used to generate monoclonal antibodies by fusing antibody-producing B cells with rapidly dividing tumour cells, this approach creates cells (hybridomas) that combine high productivity with continuous cell division (
As part of WP3, Geodia barretti cells will be fused with compound-producing marine invertebrate cells that currently lack the ability to divide in culture (Fig.
Illustrating sponge hybridoma principle. Uncultivable sponge cells that produce compounds of interest, simplified by the asterisks (A) can be fused with a sponge cell line from another species (B) to create a hybrid cell line (C) that inherits both traits, immortality and bioactive compound production (
Process intensification involves enhancing the productivity of a given process or output, ultimately leading to greater efficiency and improved sustainability. Within BLUES, process intensification is a core objective integrated across all work packages. To maximise cell density and biomaterial yields, culture conditions must be carefully tailored to each species and target product. Key parameters requiring optimisation include vessel type, temperature, oxygen and carbon dioxide concentrations, pH and agitation.
Most biopharmaceuticals, including monoclonal antibodies produced in CHO cells, are manufactured in large (up to 25,000 litres) stirred-tank bioreactors (
Two-dimensional (2D) cell culture remains a widely used, reliable and reproducible method for studying cellular behaviour. However, 2D systems fall short in replicating the structural and functional complexity of in vivo environments. They lack the 3D microarchitecture and the dynamic cellular interactions present within a biologically active extracellular matrix. In contrast, 3D cultures provide a more physiologically relevant environment, allowing cells to interact with each other and with the surrounding matrix, simulating mechanical and biochemical stimuli found in living tissues (
Within the scope of the marine invertebrate groups studied in this project, various materials have been investigated for 3D scaffold development. From sponges, various compounds, such as bio-silica (
The aggregation and proliferation of sponge cells are mediated by their interaction with specific components of the ECM, as well as with biominerals (
The objectives of WP4 are to replicate in vitro the native expression of invertebrate metabolites by focusing on several key areas, including molecular characterisation of the extracellular matrix from the targeted invertebrate species (primarily sponges and echinoderms), development of 3D cell culture matrices using widely available and sustainable marine-derived materials, enhancement of these matrices through the incorporation of ECM-specific components tailored to each taxon and functionalisation of the 3D templates with invertebrate cell growth factors to promote optimal cell proliferation and metabolite expression.
Building on the outcomes from WP2-5, WP6 will focus on developing bioprocess designs for scale-up of metabolite production for BLUES’s species of interest. These designs will incorporate flowsheets and detailed mass and energy balances covering production, extraction and the recirculation of growth media and solvents. For one selected phylum, process feasibility will be demonstrated at TRL5. A model-based approach will guide experimental design, with results feeding back into the model, to refine and optimise the process, thus applying an iterative Design-Build-Test-Learn methodology. This will begin at the laboratory scale, followed by biomass production and extraction in small-scale pilot setups.
The resulting process designs developed in WP6 will be used to assess scalability through scenario analysis developed at various production scales. These scenarios will provide information for a techno-economic assessment that considers not only mass and energy flows, but also cost factors to evaluate economic viability and identify potential economic bottlenecks. Identifying these constraints will help establish research targets for future development. This analysis will not only be done on the economic aspects, but further on environmental sustainability such as energy and water consumption and CO2 footprint.
The foundational principles of marine invertebrate cell line cultures have only recently been uncovered. BLUES advances this emerging field by deepening the understanding of the underlying molecular and biological mechanisms, which will drive improvements in both processes and end-products. Beyond this, BLUES extends industrial-scale process design to additional target species, laying the groundwork for the development of new production chassis for unique and complex marine metabolites. The project moves beyond basic research by integrating these insights with scalable production technologies, efficient product recovery and the recirculation of side streams. This integrated approach will provide information for the creation of a strategic roadmap to guide the continued advancement and implementation of innovations in blue biotechnology.
The BLUES project is set to transform the production of marine-derived compounds by replacing traditional wild harvesting with sustainable, in vitro cultivation techniques. This shift not only safeguards marine biodiversity, but also empowers the blue bioeconomy to develop valuable natural products for healthcare and industrial use. With a multidisciplinary team of experts, the project is well-positioned to deliver high-impact research and promote meaningful collaboration.
In addition to its scientific advancements, BLUES is committed to educating marine professionals and informing global policy-makers. By raising public awareness about marine conservation and connecting science with policy and society, the project supports both environmental stewardship and the advancement of health-related innovation.
Conceptualisation, Methodology and Writing have been done by all authors according to their background. All authors have read and approved the final text.
HORIZION-CL6-2023-CIRCBIO-01 ‘Bioprocesses for Metabolite Production from Marine Invertebrate Cell Lines’ (BLUES), Project number: 101134820 - https://projectblues.eu/.